François Mach
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
François Mach has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
B Kwak
Cardiology Division, Department of Medicine, University Hospital, Geneva Medical School, Foundation for Medical Research, Geneva, Switzerland
1 shared publicationBrenda R. Kwak
From the Division of Cardiology, Foundation for Medical Research, University Hospital, Geneva Medical School, Geneva, Switzerland
1 shared publicationF Mulhaupt
Cardiology Division Department of Medicine Geneva Medical School University Hospital Foundation for Medical Research Geneva Switzerland
1 shared publicationG Pelli
Cardiology Division Department of Medicine Geneva Medical School University Hospital Foundation for Medical Research Geneva Switzerland
1 shared publicationN Veillard
Cardiology Division Department of Medicine Geneva Medical School University Hospital Foundation for Medical Research Geneva Switzerland
1 shared publication
Latest Publications
- 1 May 2002
- Published by Elsevier in Transplant Immunology
- Vol. 9 (2-4) , 197-200
Statins as immunomodulators
- 1 May 2002
- Published by Elsevier in Transplant Immunology
- Vol. 9 (2-4) , 197-200
Statins as immunomodulators
- 1 August 2001
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 21 (8) , 1256-1258
Statins Inhibit Leukocyte Recruitment
- 1 August 2001
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 21 (8) , 1256-1258
Statins Inhibit Leukocyte Recruitment
- Open Access
- 30 June 2001
- Published by MDPI AG in Cardiovascular Medicine
- Vol. 4 (3) , 160-168
L’athérosclérose est une maladie inflammatoire
Atherosclerosis and its devastating clinical complications such as acute myocardial infarction, brain ischaemia or aortic aneurysm, accounts for the majority of morbidity and mortality in the adult population. Recently, several clinical and morphological studies have demonstrated that the functional state of atherosclerotic lesion (cellular composition) rather than the degree of stenosis determines the propensity for development of future clinical symptoms. Endothelial dysfunction due to causes such as hypertension, diabetes, smoking, or dyslipidaemia, leads to recruitment and activation of inflammatory cells such as monocyte/macrophages and T lymphocytes within the artery wall. By exploring and better understanding arterial inflammation, we might be able to gain insight into the process of atherosclerosis, and therefore suggest new therapeutic approaches for this disease. L’athérosclérose, et ses complications tragiques (infarctus aigu du myocarde, accident vasculaire cérébral), est devenue depuis quelques années la première cause de morbidité et de mortalité de la population adulte. Suite à l’agression de la barrière endothéliale par différents facteurs (tabagisme, dyslipidémie, hypertension, diabète, facteurs hémodynamiques), il survient un recrutement dans la paroi vasculaire de cellules inflammatoires de type monocyte/macrophages et lymphocytes T. Une fois pénétrées dans la paroi vasculaire, ces cellules sont activées et sécrètent des molécules pro-inflammatoires qui vont participer et entraîner une inflammation intra-vasculaire chronique. C’est donc la présence et l’activation de cellules inflammatoires qui vont conditionner la survenue de symptômes cliniques. L’inflammation permet de mieux comprendre les mécanismes de l’athérosclérose depuis la formation de la plaque jusqu’à la survenue de complications thrombo-occlusives.
- 30 June 2001
- Published by MDPI AG in Cardiovascular Medicine
- Vol. 4 (3) , 160-168
Open AccessL’athérosclérose est une maladie inflammatoire
Atherosclerosis and its devastating clinical complications such as acute myocardial infarction, brain ischaemia or aortic aneurysm, accounts for the majority of morbidity and mortality in the adult population. Recently, several clinical and morphological studies have demonstrated that the functional state of atherosclerotic lesion (cellular composition) rather than the degree of stenosis determines the propensity for development of future clinical symptoms. Endothelial dysfunction due to causes such as hypertension, diabetes, smoking, or dyslipidaemia, leads to recruitment and activation of inflammatory cells such as monocyte/macrophages and T lymphocytes within the artery wall. By exploring and better understanding arterial inflammation, we might be able to gain insight into the process of atherosclerosis, and therefore suggest new therapeutic approaches for this disease. L’athérosclérose, et ses complications tragiques (infarctus aigu du myocarde, accident vasculaire cérébral), est devenue depuis quelques années la première cause de morbidité et de mortalité de la population adulte. Suite à l’agression de la barrière endothéliale par différents facteurs (tabagisme, dyslipidémie, hypertension, diabète, facteurs hémodynamiques), il survient un recrutement dans la paroi vasculaire de cellules inflammatoires de type monocyte/macrophages et lymphocytes T. Une fois pénétrées dans la paroi vasculaire, ces cellules sont activées et sécrètent des molécules pro-inflammatoires qui vont participer et entraîner une inflammation intra-vasculaire chronique. C’est donc la présence et l’activation de cellules inflammatoires qui vont conditionner la survenue de symptômes cliniques. L’inflammation permet de mieux comprendre les mécanismes de l’athérosclérose depuis la formation de la plaque jusqu’à la survenue de complications thrombo-occlusives.
- 1 May 2001
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 3 (3) , 243-251
The role of chemokines in atherosclerosis
Recruitment of mononuclear leukocytes and the migration, growth, and activation of the multiple cell types within atherosclerotic lesions are critical features of the chronic inflammatory and fibroproliferative response central to atherosclerosis. Attraction of leukocyte to tissues is controlled by chemokines, whose presence is well documented in atherosclerotic lesions. Studies using knockout and transgenic murine models have demonstrated that chemokine receptor/ligand interactions are of crucial importance in the development of atherosclerosis. Beyond their chemotactic effect on mononuclear leukocytes, chemokines may also interfere with smooth muscle cell migration and growth, as well as platelet activation and other well-defined features of the atherosclerotic process. There is no doubt that the identification of chemokines as important vascular signals has provided insights into our understanding of basic cellular and molecular mechanism of atherosclerosis. Thus, there is evidence that chemokine receptor/ligands could be identified as potential new targets for therapeutic intervention to prevent or control atherosclerosis in the near future.
- 1 May 2001
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 3 (3) , 243-251
The role of chemokines in atherosclerosis
Recruitment of mononuclear leukocytes and the migration, growth, and activation of the multiple cell types within atherosclerotic lesions are critical features of the chronic inflammatory and fibroproliferative response central to atherosclerosis. Attraction of leukocyte to tissues is controlled by chemokines, whose presence is well documented in atherosclerotic lesions. Studies using knockout and transgenic murine models have demonstrated that chemokine receptor/ligand interactions are of crucial importance in the development of atherosclerosis. Beyond their chemotactic effect on mononuclear leukocytes, chemokines may also interfere with smooth muscle cell migration and growth, as well as platelet activation and other well-defined features of the atherosclerotic process. There is no doubt that the identification of chemokines as important vascular signals has provided insights into our understanding of basic cellular and molecular mechanism of atherosclerosis. Thus, there is evidence that chemokine receptor/ligands could be identified as potential new targets for therapeutic intervention to prevent or control atherosclerosis in the near future.
- Open Access
- 27 January 2001
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 131 (0304) , 41-46
The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells
HMG-CoA reductase inhibitors, or statins, are lipid-lowering agents that have been shown to effectively decrease severe rejection periods and development of transplant coronary artery disease after heart transplantation. Precise regulation of major histocompatibility complex class II (MHC class II) gene expression plays a pivotal role in control of the immune response after transplantation. The aim of this study was to evaluate the potential role of HMG-CoA reductase inhibitors in regulating the immune response. We have examined the effects of simvastatin on MHC class II expression in primary human endothelial cells. Using RNAse protection assay and flow cytometry, we observed that simvastatin dose-dependently reduced interferon-gamma (IFN-gamma) induced MHC class II expression (mRNA and protein). In contrast, simvastatin did not affect the expression of MHC class I, pointing to specific actions in the MHC class II signalling cascade. The transcriptional coactivator CIITA is the general regulator of both constitutive and inducible MHC class II expression. After stimulation with IFN-gamma, the CIITA gene is selectively activated via one (promotor IV) of its four promoters. Interestingly, mRNA levels of CIITA were decreased after treatment with simvastatin. In addition, using transient transfections of promoter-reporter constructs we observed that the activity of CIITA promoter IV was decreased by simvastatin. In conclusion, simvastatin selectively decreases IFN-gamma-induced MHC class II expression in human primary endothelial cells through actions on the CIITA promoter IV. Thus, the beneficial effects of statins reported after heart transplantation may result from this immunosuppressive action, suggesting possible therapeutic use for other immunological disorders as well.
- 27 January 2001
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 131 (0304) , 41-46
Open AccessThe HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells
HMG-CoA reductase inhibitors, or statins, are lipid-lowering agents that have been shown to effectively decrease severe rejection periods and development of transplant coronary artery disease after heart transplantation. Precise regulation of major histocompatibility complex class II (MHC class II) gene expression plays a pivotal role in control of the immune response after transplantation. The aim of this study was to evaluate the potential role of HMG-CoA reductase inhibitors in regulating the immune response. We have examined the effects of simvastatin on MHC class II expression in primary human endothelial cells. Using RNAse protection assay and flow cytometry, we observed that simvastatin dose-dependently reduced interferon-gamma (IFN-gamma) induced MHC class II expression (mRNA and protein). In contrast, simvastatin did not affect the expression of MHC class I, pointing to specific actions in the MHC class II signalling cascade. The transcriptional coactivator CIITA is the general regulator of both constitutive and inducible MHC class II expression. After stimulation with IFN-gamma, the CIITA gene is selectively activated via one (promotor IV) of its four promoters. Interestingly, mRNA levels of CIITA were decreased after treatment with simvastatin. In addition, using transient transfections of promoter-reporter constructs we observed that the activity of CIITA promoter IV was decreased by simvastatin. In conclusion, simvastatin selectively decreases IFN-gamma-induced MHC class II expression in human primary endothelial cells through actions on the CIITA promoter IV. Thus, the beneficial effects of statins reported after heart transplantation may result from this immunosuppressive action, suggesting possible therapeutic use for other immunological disorders as well.
- 1 July 2000
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 20 (7) , 1699-1700
Toward New Therapeutic Strategies Against Neointimal Formation in Restenosis
- 1 July 2000
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 20 (7) , 1699-1700
Toward New Therapeutic Strategies Against Neointimal Formation in Restenosis